Probiotic method and composition for maintaining a healthy vaginal microbiome
A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual employing a probiotic method and composition for maintaining a healthy vaginal microbiome, with particular embodiments including a bacterial formulation of at least two live bacteria selected from the group consisting of L. reuteri, L johnsonii and L. crispatus , and at least one prebiotic having glycogen as a component thereof. The bacterial formulation is administered to an individual's vagina in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists, thereby reducing inflammation in the individual's vagina. Certain embodiments include increasing the production of SCFAs in the individual's gut microbiome, while reducing the production of SCFAs in the individual's vagina and introducing ammonia oxidizing microorganisms to the individual's vagina.
1. A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual, comprising:
providing a bacterial formulation that includes at least two of a live bacteria selected from the group consisting of Lactobacillus reuteri, Lactobacillus johnsonii and Lactobacillus crispatus , wherein said bacterial formulation includes at least one prebiotic having glycogen as a component thereof;
administering the bacterial formulation to an individual's vagina in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists to thereby reduce inflammation in the individual's vagina; and
administering to the individual an extract derived from a helminth selected from the group consisting of Capillaria hepatica, Dicrocoelium dendriticum, Ascaris lumbricoides, Enterobius vermicularis, Trichuris trichiura, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Haemonchus contortus , and Trichinella spiralis.
2. The method of claim 1 , wherein the bacterial formulation includes Lactobacillus crispatus and optionally further includes a moisturizer, and wherein the bacterial formulation is applied to an individual's vagina at night so that it remains thereon during a sleeping pattern of the individual.
3. The method as set forth in claim 1 , further comprising administering at least one of tomatidine and rapamycin to the individual.
4. The method of claim 3 , wherein at least one of tomatidine and rapamycin are administered by using a bioadhesive strip that has a first and second side, the second side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 1 hour, said strip including at least one polymer selected from the group consisting of pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, sodium alginate, polyethylene glycol, tragacanth gum, guar gum, acacia gum, arabic gum, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, chitin, chitosan, levan, elsinan, collagen, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof.
5. The method as set forth in claim 1 , wherein the individual is a postmenopausal woman.
6. The method as set forth in claim 1 , further comprising, prior to the step of providing said bacterial formulation, reducing the number of bacteria in the individual using one of an antibiotic, a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system.
7. The method as set forth in claim 1 , further comprising increasing in the individual's vagina a population of bacteria selected from the group consisting of bacteria of the genera Lactobacillus, Brevundimonas , and Odoribacter and decreasing a population of bacteria of the genus Streptococcus.
8. The method as set forth in claim 1 , further comprising reducing in the individual's vagina a population level of the bacterium Gardnerella vaginalis.
9. The method as set forth in claim 1 , further comprising preserving mucus in the individual's vagina by reducing a population of bacteria in the individual's vagina selected from the group consisting of Prevotella, Gardnerella , and Bacteroides.
10. The method as set forth in claim 1 , further comprising, during a seventh month of pregnancy, reducing a population of Veillonella and Lachnospira bacteria in the individual's vagina so as to reduce a risk of a newborn infant developing one of infantile asthma, wheezing and allergies.
11. The method as set forth in claim 1 , further comprising increasing a level of butyrate in a gut microbiome of the individual and providing tributyrin to said individual.
12. The method as set forth in claim 1 , further comprising reducing a population in the individual's vagina of at least two bacteria selected from the group consisting of Peptococcus, Dialister, Gardnerella vaginalis, Bacteroides and Clostridium.
13. The method as set forth in claim 1 , further comprising reducing the amount of short chain fatty acid (SCFA) production in the individual's vagina by reducing a population of at least two of the following: Streptococcus, Bacteroides, Prevotella, Mycoplasma, Ureaplasma, Finegoldia, Mobiluncus, Leptotrichia, Eggerthella, Veillonella, Dialister, Atopobium, Megasphaera, Sneathia, C. albicans and Gardnerella vaginalis.
14. The method as set forth in claim 1 , further comprising increasing the production of SCFAs in the individual's gut microbiome, while reducing the production of SCFAs in the individual's vagina.
15. The method as set forth in claim 1 , further comprising introducing ammonia oxidizing microorganisms to the individual's vagina.
16. The method as set forth in claim 1 , further comprising, using probiotics, reducing hypoxic conditions of the individual's vagina to reduce an existing population of anaerobic bacteria in their vagina.